Publicacións (41) Publicacións de Laura Salgado Boquete

2024

  1. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study

    Actas Dermo-Sifiliograficas

  2. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients

    Journal of the European Academy of Dermatology and Venereology

  3. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Adenopatías retroauriculares y escara necrótica en cuero cabelludo, una combinación sospechosa: (Pag.-e 101822)

    Semergen: revista española de medicina de familia, Núm. 1, pp. 10-10

  2. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  3. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  4. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  5. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  6. Retroauricular lymphadenopathy and scalp eschar, a suspicious combination

    Semergen, Vol. 49, Núm. 1

  7. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  8. The DERMACLEAR study: Verification results of a natural language processing system in dermatology

    JEADV Clinical Practice, Vol. 2, Núm. 4, pp. 775-785

  9. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study

    Dermatologic Therapy

  2. Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 — Management of Special Populations, Patients With Comorbid Conditions, and Risk

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 6, pp. 583-609

  3. Selección de objetivos para la estimulación cerebral profunda en la esquizofrenia resistente al tratamiento

    Informaciones psiquiátricas: Publicación científica de los Centros de la Congregación de Hermanas Hospitalarias del Sagrado Corazón de Jesús, Núm. 246, pp. 82-95

2021

  1. A new classification of the severity of psoriasis: What’s moderate psoriasis?

    Life, Vol. 11, Núm. 7

  2. Hospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution

    Journal of drugs in dermatology : JDD, Vol. 20, Núm. 2, pp. 208-214

  3. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study

    Journal of Dermatological Treatment, Vol. 32, Núm. 3, pp. 286-290

  4. Multidisciplinary Management of the Adverse Effects of Apremilast

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 2, pp. 134-141

  5. Obesity — A Risk Factor for Psoriasis and COVID-19

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 6, pp. 489-494